メリーランド州におけるクローン病の臨床試験
メリーランド州内の拠点で、クローン病に関する15件の研究が参加者を募集しています。
メリーランド州内の都市
公式研究テキスト（英語）
Longitudinal Immunophenotyping of Patients With Inflammatory Bowel Disease
- National Institutes of Health Clinical Center, Bethesda
被験者募集中観察研究
18歳〜85歳 · 全性別 · 2026/10/02更新 · NCT07619547A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- Walter Reed National Military Medical Center ( Site 5006), Bethesda
被験者募集中第3相
16歳〜80歳 · 全性別 · 2026/10/02更新 · NCT06430801A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- Capital Digestive Care, Chevy Chase
- Woodholme Gastroenterology, Glen Burnie
被験者募集中第4相
18歳〜80歳 · 全性別 · 2026/09/30更新 · NCT06581328Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- Metropolitan Gastroenterology Group - Chevy Chase /ID# 265877, Chevy Chase
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/09/25更新 · NCT06548542A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
- Woodholme Gastroenterology Associates, Glen Burnie
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07499232A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
- Chevy Chase Clinical Research, Chevy Chase
- Woodholme Gastroenterology Associates, Glen Burnie
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07196722A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
- Woodholme Gastroenterology Associates, Glen Burnie
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/09/25更新 · NCT06233461Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Capital Digestive Care - Chevy Chase, Chevy Chase
被験者募集中第3相
18歳〜70歳 · 全性別 · 2026/09/24更新 · NCT06937099Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
- National Cancer Institute Developmental Therapeutics Clinic, Bethesda
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/23更新 · NCT03816345An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Mercy Medical Center, Baltimore-Site Number: 8400117, Baltimore
- Mid-Atlantic GI Research, LLC-Site Number: 8400106, Laurel
被験者募集中第3相
16歳〜80歳 · 全性別 · 2026/09/23更新 · NCT07184931An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab
- National Institutes of Health Clinical Center, Bethesda
被験者募集中第1/2相
18歳〜65歳 · 全性別 · 2026/08/27更新 · NCT03167437Zymfentra (Infliximab-dyyb) REal World Cohort STudy
- Mercy Medical Center, Baltimore
被験者募集中観察研究
18歳以上 · 全性別 · 2026/08/05更新 · NCT07237516Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
- The Johns Hopkins Children's Medical Center, Baltimore
被験者募集中第4相
6歳〜17歳 · 全性別 · 2026/05/27更新 · NCT05781152A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
- Woodholme Gastroenterology Associates, Glen Burnie
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/05/22更新 · NCT06764615A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
- Johns Hopkins University, Baltimore
被験者募集中第3相
2歳〜17歳 · 全性別 · 2026/05/05更新 · NCT04779320ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。